Sagimet Plans Move To Phase III In NASH By Year-End

Sagimet reported positive Phase IIb data for denifanstat in non-alcoholic steatohepatitis that may place the once-daily, oral drug as a serious competitor in a disease that at present has no approved drug therapy.